» Articles » PMID: 36407458

Pathophysiology and Management of Valvular Disease in Patients with Destination Left Ventricular Assist Devices

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Over the last two decades, implantable continuous flow left ventricular assist devices (LVAD) have proven to be invaluable tools for the management of selected advanced heart failure patients, improving patient longevity and quality of life. The presence of concomitant valvular pathology, including that involving the tricuspid, mitral, and aortic valve, has important implications relating to the decision to move forward with LVAD implantation. Furthermore, the presence of concomitant valvular pathology often influences the surgical strategy for LVAD implantation. Concomitant valve repair or replacement is not uncommonly required in such circumstances, which increases surgical complexity and has demonstrated prognostic implications both short and longer term following LVAD implantation. Beyond the index operation, it is also well established that certain valvular pathologies may develop or worsen over time following LVAD support. The presence of pre-existing valvular pathology or that which develops following LVAD implant is of particular importance to the destination therapy LVAD patient population. As these patients are not expected to have the opportunity for heart transplantation in the future, optimization of LVAD support including ameliorating valvular disease is critical for the maximization of patient longevity and quality of life. As collective experience has grown over time, the ability of clinicians to effectively address concomitant valvular pathology in LVAD patients has improved in the pre-implant, implant, and post-implant phase, through both medical management and procedural optimization. Nevertheless, there remains uncertainty over many facets of concomitant valvular pathology in advanced heart failure patients, and the understanding of how to best approach these conditions in the LVAD patient population continues to evolve. Herein, we present a comprehensive review of the current state of the field relating to the pathophysiology and management of valvular disease in destination LVAD patients.

Citing Articles

Recent Developments in Ventricular Assist Device Therapy.

Moctezuma-Ramirez A, Mohammed H, Hughes A, Elgalad A Rev Cardiovasc Med. 2025; 26(1):25440.

PMID: 39867170 PMC: 11760545. DOI: 10.31083/RCM25440.


Special Considerations for Advanced Heart Failure Surgeries: Durable Left Ventricular Devices and Heart Transplantation.

Akbar A, Zhou A, Wang A, Feng A, Rizaldi A, Ruck J J Cardiovasc Dev Dis. 2024; 11(4).

PMID: 38667737 PMC: 11050210. DOI: 10.3390/jcdd11040119.

References
1.
Pak S, Uriel N, Takayama H, Cappleman S, Song R, Colombo P . Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. J Heart Lung Transplant. 2010; 29(10):1172-6. DOI: 10.1016/j.healun.2010.05.018. View

2.
Pal J, Klodell C, John R, Pagani F, Rogers J, Farrar D . Low operative mortality with implantation of a continuous-flow left ventricular assist device and impact of concurrent cardiac procedures. Circulation. 2009; 120(11 Suppl):S215-9. DOI: 10.1161/CIRCULATIONAHA.108.844274. View

3.
Atkins B, Hashmi Z, Ganapathi A, Harrison J, Hughes G, Rogers J . Surgical correction of aortic valve insufficiency after left ventricular assist device implantation. J Thorac Cardiovasc Surg. 2013; 146(5):1247-52. DOI: 10.1016/j.jtcvs.2013.05.019. View

4.
Arias E, Bhan A, Lim Z, Mullen M . TAVI for Pure Native Aortic Regurgitation: Are We There Yet?. Interv Cardiol. 2019; 14(1):26-30. PMC: 6406131. DOI: 10.15420/icr.2018.37.1. View

5.
Callington A, Long Q, Mohite P, Simon A, Mittal T . Computational fluid dynamic study of hemodynamic effects on aortic root blood flow of systematically varied left ventricular assist device graft anastomosis design. J Thorac Cardiovasc Surg. 2015; 150(3):696-704. DOI: 10.1016/j.jtcvs.2015.05.034. View